Navigation Links
Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs. Angiographic Guidance of Stent Deployment in Patients with Multivessel Disease
Date:10/22/2007

WASHINGTON, Oct. 22 /PRNewswire/ -- Patient enrollment is complete in the first randomized, prospective, multicenter trial that will compare the clinical outcomes and cost-effectiveness of a physiologic-guided percutaneous coronary intervention (PCI) strategy to an angiographic-guided one in patients with multivessel coronary artery disease (CAD). Bernard De Bruyne, M.D., Ph.D., presented the study update today at the Transcatheter Cardiovascular Therapeutics symposium (TCT 2007) in Washington.

One thousand patients at 20 centers worldwide are participating in the FAME (Fractional flow reserve vs. Angiography for Multivessel Evaluation) study. Participants enrolled in the study meet the following criteria:

-- Coronary lesions in at least two of the three major cardiac vessels

have narrowings of greater than or equal to 50 percent by visual

assessment.

-- The lesions require stenting, according to the investigator.

-- The vessels are large enough to accommodate drug-eluting stents.

After an investigator's visual assessment of an angiogram and notation of which lesions appear to require stenting, patients will be assigned randomly to one of the two PCI strategies. Patients assigned to angiographic guidance will undergo stenting as planned, while patients assigned to physiologic guidance will have fractional flow reserve (FFR) measured in diseased vessels with a coronary pressure wire using a system provided by Radi Medical Systems AB. If FFR is less than or equal to 0.80, meaning the coronary pressure or flow beyond the narrowing is less than or equal to 80% of what it should be, the lesion will be stented.

The study's primary endpoint is a composite of major adverse cardiac events (MACE), including death, myocardial infarction and repeat coronary revascularization at one year. Secondary endpoints include global cost effectiveness after one year, cardiac death and myocardial infarction rate at one year, fu
'/>"/>

SOURCE Radi Medical Systems AB
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Monitoring Patient Glucose Levels: New Advances in software make it easier
2. Managing Preanalytical Processes for Patient Safety
3. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
4. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
5. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... PharmaTech (Cayman) Inc. (NYSE: WX ), a leading ... in China and the ... financial results for the second quarter of 2014 after the ... (which will be Thursday morning, August 14, 2014 Shanghai time). ... section of the Company,s website at http://www.wuxiapptec.com . ...
(Date:7/22/2014)... SOUTH EASTON, Mass. , July 22, ... ("PBI" or the "Company") and Parabase Genomics ... have entered into a strategic research and ... of the collaboration, PBI will develop a ... neonatal molecular diagnostics and newborn confirmatory testing ...
(Date:7/22/2014)... , July 22, 2014 ... umfassenden Schutz von Pharmazeuten und Krankenpflegern ... Equashield ( http://www.equashield.com ), ... System Transfer Devices, CSTDs) für gefährliche Medikamente, ernannte ... und Hersteller von medizinischen Produkten, zu seinem ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... Cheyenne Regional Medical Center is expanding its ... an AirLife Denver medical helicopter service in ... Regional and HCA-HealthONE, which operates AIRLIFE Denver. ... blue and sonic green helicopter will be stationed in ...
... Systems, Inc. (Nasdaq: DCTH ) announced today that ... Lazard Capital Markets, Eighth Annual Healthcare Conference on Tuesday, November ...  Mr. Hobbs will provide an overview of the Company,s business ... this conference is by invitation only.  Delcath will offer a ...
Cached Medicine Technology:Cheyenne Regional Medical Center Announces New Air Ambulance Service Partnership with HealthONE's AirLife Denver 2Cheyenne Regional Medical Center Announces New Air Ambulance Service Partnership with HealthONE's AirLife Denver 3Delcath to Present at the Lazard Healthcare Conference on November 15 2Delcath to Present at the Lazard Healthcare Conference on November 15 3
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will ... Agency for the 2014-2015 fiscal year. He joined the ... states, "“Serving on the HASA board has given me a ... me remember how much others need help." , ABOUT AARON ... has a B.S. in Finance from the University of Delaware. ...
(Date:7/22/2014)... Society of Hematology (ASH) will honor Tomas Ganz, MD, ... with the 2014 E. Donnall Thomas Lecture for his ... the iron-regulatory hormone hepcidin and investigation of its roles ... Prize Laureate and past Society president E. Donnall Thomas, ... represented a paradigm shift or significant discovery in the ...
(Date:7/22/2014)... at the University of Utah,s John A. Moran Eye ... Eye Research (ISER) as the recipient of the Houston, ... in Retina Research., The award recognizes lifetime achievement by ... to the understanding of vitreoretinal diseases or disorders. The ... Biennial Meeting in San Francisco, where Marc will deliver ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC News, ... favorite beauty products, “ Botox , that’s pretty much it.” ... has changed my life” by halving the amount of ... various, daily appearances. “Suddenly my eyelids are no longer ... “I think that Kelly Ripa’s response to the question was ...
(Date:7/22/2014)... American Conference on Lung Cancer (LALCA 2014) will be ... , Lung Cancer is still the leading cause of ... on the success of the previous conferences in Chile, ... discuss the science and advances in the treatment and ... Latin America in particular. , With tobacco being the ...
Breaking Medicine News(10 mins):Health News:New Board President for Baltimore-based Nonprofit 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2
... Dr. Lawyer will lead clinical efforts of the ... KePRO, a national medical,management firm, appointed Lenaye ... Dr. Lawyer will oversee all clinical aspects of ... Harrisburg,office., "Dr. Lawyer has practiced her entire ...
... the Northeast region with more hires,planned throughout the ... Aug. 28 The Pennsylvania,Patient Safety Authority has ... to help healthcare facilities that report to the,Pennsylvania ... Pennsylvania citizens., "Last year in focus groups ...
... 67%, but patients and doctors say drug is hard to ... percent of patients with atrial fibrillation, a known risk factor ... anti-clotting drug warfarin, a new study found. , Among those ... prevent a stroke. And an additional 25 percent were taking ...
... growing professional and consumer markets in China. , ... ... international venture capital firm, today announced that together with Mustang Ventures, ... of financing for Profex.Inc. Trident Capital & Mustang Ventures jointly invested ...
... HAYWARD, Calif., Aug. 28 Guava Technologies, Inc.,announced ... Group to,provide drug discovery researchers with an automated ... key component of a larger,strategic initiative by Guava ... voiced need for sophisticated cell analysis technology to,support ...
... increased plaque , , THURSDAY, Aug. 28 (HealthDay News) -- A ... in the brain that is thought to play a key ... the protein, known as amyloid beta, was directly linked to ... When brain cell communication increased, so did amyloid beta. When ...
Cached Medicine News:Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 2Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 3Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 3Health News:Scientists Track Hourly Changes in Alzheimer's Protein 2
Easy to use , Allow for a flexible washing , Uniform and efficient , Very robust and reliable , Adjustable to all well shapes , Rack included (not autoclavable) , Autoclavable at 121C , No e...
... with a 25-microplate capacity ... and aspiration and dispense ... On-board software for user ... programs. External vacuum pump ...
... microplate washers available to handle ... cell-based assays. Embla 384 Cell ... have been optimized to avoid ... robotic compatible and have been ...
ELISA Microplate Washer, Manual...
Medicine Products: